Postoperative telephone clinic can offer similar benefits to in-person care

Taking time to drive to the doctor’s office, wait for the doctor, go through the appointment and drive home—that's a lot to ask after having surgery. Telephone postoperative clinics at Veterans Affairs facilities aim to ease this burden.

A checkup after minor surgery can easily be done via telehealth and provide the same level of care as an in-office visit. In a study that compared pre- and postoperative visits using telephone care, results found that a call is just as effective as an office visit. The study was published in the Journal of the American College of Surgeons.

In a study of 200 patients, 29 pre-interventions and 171 post-interventions, use of in-person clinics decreased from 0.83 visits per eligible patient to 0.4 after the implementation of the telehealth clinic. Nearly 90 percent of patients who completed telephone consultations were discharged and 11 percent were escalated to a repeat phone call or a clinic visit.

"We are pleased with the results of this intervention, which has increased access to care while mitigating long travel distances and inconvenience for many of our patients," said lead author Kristy Kummerow Broman, MD, MPH, a general surgery resident at Vanderbilt University in Nashville, Tennessee.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.